Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TechnologyAdvice

- PMLiVE

GSK eyes first-line use for leukaemia drug Arzerra

Positive phase III trial results back regulatory filings for earlier use

- PMLiVE

PhRMA deputy VP returns to World Health Advocacy

Christoper Ward is appointed senior partner at health policy specialist agency he founded

- PMLiVE

Eylea set to challenge Lucentis in UK after NICE recommendation

Bayer’s medicine recommended for NHS use to treat wet AMD

- PMLiVE

Translating value in pharma marketing

A new approach to marketing could build upon Kotler's idea of 'exchanging value' to bring genuine beneficial outcomes for customers, patients and society at large

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

EU flag

EU Parliament panel backs updated clinical trials regulations

But pharma industry concerned about measures to increase transparency

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

GSK boost vaccines capabilities with €250m Okairos purchase

Acquires novel platform technology and several early stage assets

- PMLiVE

Allergan veteran joins Kala as head of business development

Charles McDermott has experience in ophthalmology

- PMLiVE

Rx insights using mobile technology

Harnessing the strengths of mobile research in pharma

- PMLiVE

Orphan status in US for Astellas/ Basilea antifungal

Isavuconazole is being developed as a treatment for invasive aspergillosis

- PMLiVE

FDA gives Alexion’s metabolic drug breakthrough status

Reduces requirements for registration, potentially speeding up approval

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links